Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-25 @ 12:44 AM
Ignite Modification Date:
2025-12-25 @ 10:56 PM
NCT ID:
NCT04285567
Pre Assignment Details:
Participants with previously untreated chronic lymphocytic leukemia (CLL) without del (17p) or tumor protein p53 (TP53) mutation were randomized in a 1:1 ratio to receive either venetoclax + obinutuzumab (VEN+G) or fludarabine, cyclophosphamide, and rituximab/bendamustine and rituximab (FCR/BR). All participants in FCR/BR arm were eligible for treatment with BR, whereas only participants ≤ 65 years were eligible for FCR. The choice between FCR or BR was at the investigator's discretion.
Recruitment Details:
A total of 166 participants took part in this study which was conducted at 38 investigative sites in France, Italy, Australia, Spain, and the United States. The study is still ongoing.
Study:
NCT04285567
Study Brief:
Results Section:
NCT04285567